Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

In the world of weight loss supplements, the quest for effective products that truly deliver results has led many to explore ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...